NEWS
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks post end-of-treatment, 94% of patients in the treatment arm achieved HBsAg levels <100 IU/mL, with 36% achieving <10 IU/mL. The treatment was generally safe, with no serious adverse events reported. The trial's results highlight the potential for Imdusiran and VTP-300 to enhance immune responses and reduce HBsAg in chronic hepatitis B patients.
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
